annual cash & cash equivalents:
$517.55M+$379.92M(+276.03%)Summary
- As of today (July 1, 2025), CPRX annual cash & cash equivalents is $517.55 million, with the most recent change of +$379.92 million (+276.03%) on December 31, 2024.
- During the last 3 years, CPRX annual cash & cash equivalents has risen by +$346.11 million (+201.88%).
- CPRX annual cash & cash equivalents is now at all-time high.
Performance
CPRX Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$580.66M+$63.10M(+12.19%)Summary
- As of today (July 1, 2025), CPRX quarterly cash & cash equivalents is $580.66 million, with the most recent change of +$63.10 million (+12.19%) on March 31, 2025.
- Over the past year, CPRX quarterly cash & cash equivalents has increased by +$270.25 million (+87.06%).
- CPRX quarterly cash & cash equivalents is now at all-time high.
Performance
CPRX quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
CPRX Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +276.0% | +87.1% |
| 3 y3 years | +201.9% | +225.5% |
| 5 y5 years | +478.2% | +470.7% |
CPRX Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +276.0% | at high | +380.0% |
| 5 y | 5-year | at high | +478.2% | at high | +404.7% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% |
CPRX Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $580.66M(+12.2%) |
| Dec 2024 | $517.55M(+276.0%) | $517.55M(+17.0%) |
| Sep 2024 | - | $442.33M(+17.7%) |
| Jun 2024 | - | $375.69M(+21.0%) |
| Mar 2024 | - | $310.41M(+125.5%) |
| Dec 2023 | $137.64M(-53.9%) | $137.64M(+13.8%) |
| Sep 2023 | - | $120.97M(-32.3%) |
| Jun 2023 | - | $178.79M(+20.6%) |
| Mar 2023 | - | $148.25M(-50.3%) |
| Dec 2022 | $298.39M(+74.0%) | $298.39M(+16.5%) |
| Sep 2022 | - | $256.06M(+21.4%) |
| Jun 2022 | - | $210.91M(+18.2%) |
| Mar 2022 | - | $178.37M(+4.0%) |
| Dec 2021 | $171.44M(+31.6%) | $171.44M(+10.7%) |
| Sep 2021 | - | $154.84M(+14.4%) |
| Jun 2021 | - | $135.29M(+6.3%) |
| Mar 2021 | - | $127.33M(-2.2%) |
| Dec 2020 | $130.24M(+45.5%) | $130.24M(+11.2%) |
| Sep 2020 | - | $117.11M(+1.8%) |
| Jun 2020 | - | $115.05M(+13.1%) |
| Mar 2020 | - | $101.75M(+13.7%) |
| Dec 2019 | $89.51M(+440.5%) | $89.51M(+99.0%) |
| Sep 2019 | - | $44.98M(+92.1%) |
| Jun 2019 | - | $23.42M(+22.7%) |
| Mar 2019 | - | $19.08M(+15.2%) |
| Dec 2018 | $16.56M(-71.2%) | $16.56M(+56.0%) |
| Sep 2018 | - | $10.62M(+7.4%) |
| Jun 2018 | - | $9.89M(-49.6%) |
| Mar 2018 | - | $19.60M(-65.9%) |
| Dec 2017 | $57.50M(+313.9%) | $57.50M(+684.5%) |
| Sep 2017 | - | $7.33M(-14.6%) |
| Jun 2017 | - | $8.58M(-14.0%) |
| Mar 2017 | - | $9.98M(-28.2%) |
| Dec 2016 | $13.89M(-50.8%) | $13.89M(-21.2%) |
| Sep 2016 | - | $17.64M(-5.8%) |
| Jun 2016 | - | $18.72M(-15.8%) |
| Mar 2016 | - | $22.23M(-21.3%) |
| Dec 2015 | $28.23M | $28.23M(-13.8%) |
| Sep 2015 | - | $32.75M(-12.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2015 | - | $37.22M(-9.9%) |
| Mar 2015 | - | $41.32M(+354.3%) |
| Dec 2014 | $9.10M(+310.5%) | $9.10M(-19.2%) |
| Sep 2014 | - | $11.26M(-23.9%) |
| Jun 2014 | - | $14.80M(+1280.1%) |
| Mar 2014 | - | $1.07M(-51.6%) |
| Dec 2013 | $2.22M(+57.2%) | $2.22M(-82.9%) |
| Sep 2013 | - | $12.96M(+1374.6%) |
| Jun 2013 | - | $879.10K(+36.1%) |
| Mar 2013 | - | $646.00K(-54.2%) |
| Dec 2012 | $1.41M(-76.6%) | $1.41M(-88.2%) |
| Sep 2012 | - | $11.97M(+59.3%) |
| Jun 2012 | - | $7.51M(+59.1%) |
| Mar 2012 | - | $4.72M(-21.7%) |
| Dec 2011 | $6.03M(+10.1%) | $6.03M(+180.2%) |
| Sep 2011 | - | $2.15M(-36.8%) |
| Jun 2011 | - | $3.41M(-50.4%) |
| Mar 2011 | - | $6.87M(+25.5%) |
| Dec 2010 | $5.48M(-29.6%) | $5.48M(-12.4%) |
| Sep 2010 | - | $6.25M(+11.4%) |
| Jun 2010 | - | $5.61M(-17.0%) |
| Mar 2010 | - | $6.76M(-13.1%) |
| Dec 2009 | $7.78M(-33.9%) | $7.78M(+58.4%) |
| Sep 2009 | - | $4.91M(-21.6%) |
| Jun 2009 | - | $6.27M(-29.8%) |
| Mar 2009 | - | $8.93M(-24.1%) |
| Dec 2008 | $11.77M(-26.2%) | $11.77M(-21.7%) |
| Sep 2008 | - | $15.03M(+14.9%) |
| Jun 2008 | - | $13.08M(-11.1%) |
| Mar 2008 | - | $14.72M(-7.7%) |
| Dec 2007 | $15.94M(-22.0%) | $15.94M(-5.6%) |
| Sep 2007 | - | $16.89M(-4.1%) |
| Jun 2007 | - | $17.60M(-7.7%) |
| Mar 2007 | - | $19.06M(-6.7%) |
| Dec 2006 | $20.43M(+2550.1%) | $20.43M(+580.4%) |
| Sep 2006 | - | $3.00M(+826.4%) |
| Jun 2006 | - | $324.20K(-58.0%) |
| Dec 2005 | $771.10K(+319.3%) | $771.10K(+319.3%) |
| Dec 2004 | $183.90K(+71.7%) | $183.90K |
| Dec 2002 | $107.10K | - |
FAQ
- What is Catalyst Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Catalyst Pharmaceuticals quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals quarterly cash & cash equivalents year-on-year change?
What is Catalyst Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of CPRX is $517.55M
What is the all time high annual cash & cash equivalents for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high annual cash & cash equivalents is $517.55M
What is Catalyst Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, CPRX annual cash & cash equivalents has changed by +$379.92M (+276.03%)
What is Catalyst Pharmaceuticals quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of CPRX is $580.66M
What is the all time high quarterly cash & cash equivalents for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high quarterly cash & cash equivalents is $580.66M
What is Catalyst Pharmaceuticals quarterly cash & cash equivalents year-on-year change?
Over the past year, CPRX quarterly cash & cash equivalents has changed by +$270.25M (+87.06%)